BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Access the interviews in their entirety at:
BIVI: https://www.redchip.com/assets/access/bivi_accessLBSR: https://www.redchip.com/assets/access/lbsr_access
In an exclusive interview, Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share how BioVie is unlocking the science of longevity through novel therapeutics targeting neurodegenerative diseases and advanced liver conditions. Do highlights the Company's lead drug candidate, bezisterim, a first-in-class small molecule designed to combat chronic inflammation and insulin resistance-key drivers in Alzheimer's and Parkinson's disease, as well as Long COVID. He also discusses BIV201, BioVie's Orphan-designated liver therapy being developed to treat - and may become the first approved treatment - for ascites, an end-stage liver disease condition of 50%+ mortality rate in 12 months. With multiple clinical programs advancing across Phase 2 and Phase 3 trials and a clear path toward commercialization, BioVie is positioned at the forefront of transformative healthcare innovation.
Pete O'Heeron, Chairman of Liberty Star, and Liberty Star board member Gerardo King, appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to highlight the Company's dual-track strategy targeting high-grade gold and large-scale copper-gold mineralization in Arizona. They discuss recent bonanza-grade assay results from the Red Rock Canyon Gold Project, where surface samples have returned values as high as 107.5 g/t gold, and the validation of a porphyry copper system at the Hay Mountain Project through Liberty Star's 2024 drill campaign. With gold prices near all-time highs and copper demand surging amid global electrification, Liberty Star is actively pursuing a joint venture to accelerate project development while minimizing shareholder dilution. The company's experienced leadership and strategic positioning in one of North America's most prolific mining regions underscore its potential to unlock significant value through near- and long-term exploration success.
BIVI and LBSR are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About BioVie Inc.
BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease and Parkinson's disease) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.
About Liberty Star
Liberty Star Uranium & Metals Corp. (LBSR:OTCQB), d/b/a Liberty Star Minerals, is an Arizona-based mineral exploration company engaged in the acquisition, exploration, and development of mineral properties in Arizona and the southwest USA. Currently the company controls properties that are located over what management considers some of North America's richest mineralized regions for copper, gold, silver, molybdenum (moly), and associated metals. The Company's premiere property is the Hay Mountain property (exploration stage) for porphyry copper, gold, moly and other commercially important minerals. Specific targets have been selected to explore for near-surface and deep-seated ore bodies, of which there are numerous analogs nearby. Contiguous with the primary Hay Mountain porphyry exploration target, and part of the overall Hay Mountain property, is an increasingly attractive area of exploration stage gold mineralization denominated Red Rock Canyon. Red Rock Canyon exhibits what we believe are extensive, promising hydrothermal associated gold-bearing structures that are documented in historical public and Company records. View numerous geoscientific reports on our website. The Hay Mountain & Red Rock Canyon properties are in Cochise County (southeast) Arizona, USA.
Follow Liberty Star Minerals on Facebook, LinkedIn & [X]Twitter
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave GentryRedChip Companies Inc.1-407-644-4256info@redchip.com
--END--
SOURCE: RedChip Companies, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
S&P/TSX composite rises Friday morning, U.S. markets also higher
TORONTO — Gains in technology stocks helped lift Canada's main stock index in late-morning trading on Friday, while U.S. markets also rose. The S&P/TSX composite index was up 59.05 points at 27,431.31. In New York, the Dow Jones industrial average was up 99.67 points at 44,793.58. The S&P 500 index was up 16.59 points at 6,379.94, while the Nasdaq composite was up 42.59 points at 21,100.55. The Canadian dollar traded for 72.97 cents US compared with 73.37 cents US on Thursday. The September crude oil contract was down 42 cents US at US$65.61 per barrel. The August gold contract was down US$40.00 at US$3,333.50 an ounce. This report by The Canadian Press was first published July 25, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) The Canadian Press Sign in to access your portfolio
Newsweek
26 minutes ago
- Newsweek
Smart Speakers Like Alexa and Google Assistant Could Tell if You Have Parkinson's
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new AI-powered, speech-based screening tool could help people assess whether they are showing signs of Parkinson's disease at home. Developed as part of a study by University of Rochester computer scientists, the web-based test asks users to recite two pangrams, short sentences using every letter of the alphabet. In just seconds, the AI can analyze the voice recordings to look for subtle patterns linked to Parkinson's—with nearly 86 percent accuracy. The researchers believe such a tool could be implemented as a feature in popular speech-based interfaces like Amazon Alexa or Google Home (with users consent). Parkinson's is typically diagnosed by specially trained neurologists through a combination of examinations, brain imaging and family history. While the new tool is not intended to be a replacement for a clinical diagnosis, the researchers see it as a fast, low-barrier and accessible way to flag people who might have the disease and encourage them to seek thorough clinical evaluation. Man connecting Alexa-like device to phone at home. Man connecting Alexa-like device to phone at 1.1 million people in the U.S. are living with Parkinson's disease, expected to rise to 1.2 million by 2030, according to Parkinson's Foundation. Nearly an estimated 90,000 people are diagnosed across the country each year, making it the second-most common neurodegenerative disease after Alzheimer's. While incidence increases with age, some four percent of people are diagnosed before 50. "There are huge swaths of the U.S. and across the globe where access to specialized neurological care is limited," said Rochester computer science professor Ehsan Hoque in a statement. "With users' consent, widely used speech-based interfaces like Amazon Alexa or Google Home could potentially help people identify if they need to seek further care." Most people living with Parkinson's in the U.S. seek their care from neurologists, with approximately 50 percent seeing a community neurologist and 9 percent seeing a movement disorders specialist, a previous Parkinson's Foundation study found. However, nearly 40 percent of people with the disease do not see a neurologist for their care but see a primary care provider (29 percent) or no provider (11 percent.) Home speaker device. Home speaker device. fabioderby/Getty Images To train and validate the new tool the researchers collected data from more than 1,300 participants—with and without Parkinson's—across home care settings, clinical settings at the University of Rochester Medical Center and the InMotion Parkinson's disease care center in Ohio. Using their computer's microphone, participants were asked to read aloud the following sentences: "The quick brown fox jumps over the lazy dog. The dog wakes up and follows the fox into the forest, but again the quick brown fox jumps over the lazy dog." By utilizing advanced semi-supervised audio models trained on millions of digital recordings to understand the characteristics of speech, the tool can obtain enough vocal cues from the short sentences to flag warning signs. "For example, the way someone with Parkinson's would utter sounds, pause, breathe, and inadvertently add features of unintelligibility is different in someone without Parkinson's," explained paper author and computer science master's degree student Abdelrahman Abdelkader in a statement. The tool was 85.7 percent accurate when tested, providing a strong indication of whether someone may have Parkinson's, according to the study authors. Woman using Google Nest-like device at home. Woman using Google Nest-like device at well as speech, some people can display signs of Parkinson's through motor movement tasks or facial expressions. Over the past decade, this has led Hoque's lab to pursue algorithms to combine multiple indicators with state-of-the-art results. "Research shows that nearly 89 percent of people with Parkinson's have a deformity in their voice that can be indicative of the disease, making speech a strong starting point for digital screening," said paper author and computer scientist Tariq Adnan in a statement. "By combining this method with assessments of other symptoms, we aim to cover the majority of people through our accessible screening process." An interactive, browser-based demonstration of the lab's three screening tests, including this new speech test, is available to try out at home here. Newsweek has reached out to the study authors for more information. Do you have a health story to share with Newsweek? Do you have a question about Parkinson's? Let us know via health@ References Adnan, T., Abdelkader, A., Liu, Z., Hossain, E., Park, S., Islam, M. S., & Hoque, E. (2025). A novel fusion architecture for detecting Parkinson's Disease using semi-supervised speech embeddings. Npj Parkinson's Disease, 11(1), 176. Pearson, C., Hartzman, A., Munevar, D., Feeney, M., Dolhun, R., Todaro, V., Rosenfeld, S., Willis, A., & Beck, J. C. (2023). Care access and utilization among medicare beneficiaries living with Parkinson's disease. Npj Parkinson's Disease, 9(1), 108.
Hamilton Spectator
39 minutes ago
- Hamilton Spectator
S&P/TSX composite rises Friday morning, U.S. markets also higher
TORONTO - Gains in technology stocks helped lift Canada's main stock index in late-morning trading on Friday, while U.S. markets also rose. The S&P/TSX composite index was up 59.05 points at 27,431.31. In New York, the Dow Jones industrial average was up 99.67 points at 44,793.58. The S&P 500 index was up 16.59 points at 6,379.94, while the Nasdaq composite was up 42.59 points at 21,100.55. The Canadian dollar traded for 72.97 cents US compared with 73.37 cents US on Thursday. The September crude oil contract was down 42 cents US at US$65.61 per barrel. The August gold contract was down US$40.00 at US$3,333.50 an ounce. This report by The Canadian Press was first published July 25, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD)
